Health-related Quality of Life and Healthcare Costs of Symptoms and Cardiovascular Disease Events in Patients with Atrial Fibrillation: a Longitudinal Analysis of 27 Countries from the EURObservational Research Programme on Atrial Fibrillation...

Overview

Journal Europace

Publisher Oxford University Press

Specialties Cardiology & Vascular Diseases
Physiology

Date 2024 May 29

PMID 38807488

Authors

Marjan Walli-Attaei

Mathew Little

Ramon Luengo-Fernandez

Alastair Gray

Aleksandra Torbica

Aldo P Maggioni

Firoozeh Bairami

Radu Huculeci

Victor Aboyans

Adam D Timmis

Panos Vardas

Jose Leal

Affiliations

Soon will be listed here.

Abstract

Aims: We examine the effects of symptoms and cardiovascular disease (CVD) events on health-related quality of life (HRQOL) and healthcare costs in a European population with atrial fibrillation (AF).

Methods And Results: In the EURObservational Research Programme on AF long-term general registry, AF patients from 250 centres in 27 European countries were enrolled and followed for 2 years. We used fixed effects models to estimate the association of symptoms and CVD events on HRQOL and annual healthcare costs. We found significant decrements in HRQOL in AF patients in whom ST-segment elevation myocardial infarction (STEMI) [-0.075 (95% confidence interval -0.144, -0.006)], angina or non-ST-elevation myocardial infarction (NSTEMI) [-0.037 (-0.071, -0.003)], new-onset/worsening heart failure [-0.064 (-0.088, -0.039)], bleeding events [-0.031 (-0.059, -0.003)], thromboembolic events [-0.071 (-0.115, -0.027)], mild symptoms [0.037 (-0.048, -0.026)], or severe/disabling symptoms [-0.090 (-0.108, -0.072)] occurred during the follow-up. During follow-up, annual healthcare costs were associated with an increase of €11 718 (€8497, €14 939) in patients with STEMI, €5823 (€4757, €6889) in patients with angina/NSTEMI, €3689 (€3219, €4158) in patients with new-onset or worsening heart failure, €3792 (€3315, €4270) in patients with bleeding events, and €3182 (€2483, €3881) in patients with thromboembolic events, compared with AF patients without these events. Healthcare costs were primarily driven by inpatient costs. There were no significant differences in HRQOL or healthcare resource use between EU regions or by sex.

Conclusion: Symptoms and CVD events are associated with a high burden on AF patients and healthcare systems throughout Europe.

Citing Articles

Integrated Care in Atrial Fibrillation: A Multidisciplinary Approach to Improve Clinical Outcomes and Quality of Life.

Machado A, Leite F, Pereira M Healthcare (Basel). 2025; 13(3).

PMID: 39942514 PMC: 11817522. DOI: 10.3390/healthcare13030325.

The crucial importance of preventive and cardiac rehabilitation programmes in patients with atrial fibrillation: AF-CARE units.

Aksit E, Kucuk U, Taylan G Europace. 2025; 27(2).

PMID: 39821014 PMC: 11795660. DOI: 10.1093/europace/euaf016.

Evolution in electrophysiology 100 years after Einthoven: translational and computational innovations in rhythm control of atrial fibrillation.

Schuijt E, Scherr D, Plank G, Schotten U, Heijman J Europace. 2024; 27(1).

PMID: 39729032 PMC: 11707389. DOI: 10.1093/europace/euae304.

Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects.

Rienstra M, Tzeis S, Bunting K, Caso V, Crijns H, De Potter T Europace. 2024; 26(12).

PMID: 39716733 PMC: 11666470. DOI: 10.1093/europace/euae298.

References

Ramos-Goni J, Craig B, Oppe M, Ramallo-Farina Y, Pinto-Prades J, Luo N . Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach. Value Health. 2018; 21(5):596-604. DOI: 10.1016/j.jval.2017.10.023. View

Wynn G, Todd D, Webber M, Bonnett L, McShane J, Kirchhof P . The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014; 16(7):965-72. PMC: 4070972. DOI: 10.1093/europace/eut395. View

White I, Royston P, Wood A . Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011; 30(4):377-99. DOI: 10.1002/sim.4067. View

Zoni Berisso M, Landolina M, Ermini G, Parretti D, Zingarini G, Degli Esposti L . The cost of atrial fibrillation in Italy: a five-year analysis of healthcare expenditure in the general population. From the Italian Survey of Atrial Fibrillation Management (ISAF) study. Eur Rev Med Pharmacol Sci. 2017; 21(1):175-183. View

Holstenson E, Ringborg A, Lindgren P, Coste F, Diamand F, Nieuwlaat R . Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. Europace. 2010; 13(1):23-30. DOI: 10.1093/europace/euq325. View

Li H, Song X, Liang Y, Bai X, Liu-Huo W, Tang C . Global, regional, and national burden of disease study of atrial fibrillation/flutter, 1990-2019: results from a global burden of disease study, 2019. BMC Public Health. 2022; 22(1):2015. PMC: 9632152. DOI: 10.1186/s12889-022-14403-2. View

Stromnes L, Ree H, Gjesdal K, Ariansen I . Sex Differences in Quality of Life in Patients With Atrial Fibrillation: A Systematic Review. J Am Heart Assoc. 2019; 8(8):e010992. PMC: 6507196. DOI: 10.1161/JAHA.118.010992. View

Kotecha D, Ahmed A, Calvert M, Lencioni M, Terwee C, Lane D . Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties. PLoS One. 2016; 11(11):e0165790. PMC: 5089715. DOI: 10.1371/journal.pone.0165790. View

Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M . Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace. 2019; 21(7):1013-1022. DOI: 10.1093/europace/euz032. View

10.

Luengo-Fernandez R, Yiin G, Gray A, Rothwell P . Population-based study of acute- and long-term care costs after stroke in patients with AF. Int J Stroke. 2012; 8(5):308-14. PMC: 6016735. DOI: 10.1111/j.1747-4949.2012.00812.x. View

11.

Witassek F, Springer A, Adam L, Aeschbacher S, Beer J, Blum S . Health-related quality of life in patients with atrial fibrillation: The role of symptoms, comorbidities, and the type of atrial fibrillation. PLoS One. 2019; 14(12):e0226730. PMC: 6927649. DOI: 10.1371/journal.pone.0226730. View

12.

Kotecha D, Piccini J . Atrial fibrillation in heart failure: what should we do?. Eur Heart J. 2015; 36(46):3250-7. PMC: 4670966. DOI: 10.1093/eurheartj/ehv513. View

13.

Wolowacz S, Samuel M, Brennan V, Jasso-Mosqueda J, van Gelder I . The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011; 13(10):1375-85. DOI: 10.1093/europace/eur194. View

14.

Bruggenjurgen B, Rossnagel K, Roll S, Andersson F, Selim D, Muller-Nordhorn J . The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health. 2007; 10(2):137-43. DOI: 10.1111/j.1524-4733.2006.00160.x. View

15.

Johnsen S, Dalby L, Tackstrom T, Olsen J, Fraschke A . Cost of illness of atrial fibrillation: a nationwide study of societal impact. BMC Health Serv Res. 2017; 17(1):714. PMC: 5681797. DOI: 10.1186/s12913-017-2652-y. View

16.

Savelieva I, Camm A . Permanent atrial fibrillation in women: the prevalent role of risk factors and specific mechanisms determining outcome and quality of life. Europace. 2020; 22(11):1603-1606. DOI: 10.1093/europace/euaa329. View

17.

Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H . Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res. 2010; 19(3):381-90. DOI: 10.1007/s11136-010-9591-y. View

18.

van Lier L, van der Roest H, Oosten B, Garms-Homolova V, Onder G, Finne-Soveri H . Predictors of Societal Costs of Older Care-Dependent Adults Living in the Community in 11 European Countries. Health Serv Insights. 2019; 12:1178632918820947. PMC: 6348544. DOI: 10.1177/1178632918820947. View

19.

Rupel V, Srakar A, Rand K . Valuation of EQ-5D-3l Health States in Slovenia: VAS Based and TTO Based Value Sets. Zdr Varst. 2020; 59(1):8-17. PMC: 7478084. DOI: 10.2478/sjph-2020-0002. View

20.

Sgreccia D, Manicardi M, Malavasi V, Vitolo M, Valenti A, Proietti M . Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. J Clin Med. 2021; 10(17). PMC: 8432492. DOI: 10.3390/jcm10173979. View